Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bexmarilimab + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Faron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bexmarilimab + nab-paclitaxel is an investigational combination therapy being developed by Faron Pharmaceuticals. Bexmarilimab is a humanized IgG4 monoclonal antibody that targets Clever-1 (Common Lymphatic Endothelial and Vascular Endothelial Receptor-1), also known as Stabilin-1. Clever-1 is an immunosuppressive receptor expressed on tumor-associated macrophages (TAMs) and endothelial cells. By inhibiting Clever-1, bexmarilimab aims to convert pro-tumoral M2 macrophages into anti-tumoral M1 macrophages, thereby activating the immune system against the tumor. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a microtubule inhibitor that interferes with cell division and induces apoptosis. The combination is being evaluated in the FINPROVE Phase 1 trial for patients with Clever-1 positive breast cancer, with the goal of enhancing chemotherapy efficacy through immune modulation and macrophage reprogramming.
- Other names
- bexmarilimab + nanoparticle albumin-bound paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))STAB1 (Common lymphatic endothelial and vascular endothelial receptor 1)
Beyond the preview
Go deeper on bexmarilimab + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bexmarilimab + nab-paclitaxel.